InMed Pharmaceuticals Inc. – NASDAQ:INM
InMed Pharmaceuticals stock price today
$2.25
-2.49
-52.53%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 5 hours
InMed Pharmaceuticals stock price monthly change
+1688.68%
month
InMed Pharmaceuticals stock price quarterly change
+1688.68%
quarter
InMed Pharmaceuticals stock price yearly change
+1109.18%
year
InMed Pharmaceuticals key metrics
Market Cap | 3.15M |
Enterprise value | N/A |
P/E | -0.05 |
EV/Sales | -6.06 |
EV/EBITDA | 0.66 |
Price/Sales | 0.65 |
Price/Book | 0.07 |
PEG ratio | N/A |
EPS | -303.27 |
Revenue | 5.03M |
EBITDA | -6.94M |
Income | -11.92M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -950.01% |
Oper. margin | -656.18% |
Gross margin | 4.46% |
EBIT margin | -656.18% |
EBITDA margin | -137.95% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeInMed Pharmaceuticals stock price history
InMed Pharmaceuticals stock forecast
InMed Pharmaceuticals financial statements
| Jun 2022 | 514.75K | -7.87M | -1528.88% |
|---|---|---|---|
| Mar 2023 | 1.03M | -1.99M | -193.24% |
| Jun 2023 | 2.31M | -338.39K | -14.64% |
| Mar 2024 | 1.17M | -1.72M | -146.93% |
| Dec 2022 | 16919696 | 2.58M | 15.28% |
|---|---|---|---|
| Mar 2023 | 14730101 | 2.34M | 15.9% |
| Jun 2023 | 14106340 | 2.01M | 14.3% |
| Mar 2024 | 13358716 | 2.25M | 16.87% |
| Jun 2022 | -3.98M | -719.34K | 4.98M |
|---|---|---|---|
| Mar 2023 | -1.65M | -128.19K | -63.69K |
| Jun 2023 | -657.93K | -33.60K | -654 |
| Mar 2024 | -1.96M | -71 | 34.79K |
InMed Pharmaceuticals alternative data
| Aug 2023 | 13 |
|---|---|
| Sep 2023 | 13 |
| Oct 2023 | 13 |
| Nov 2023 | 13 |
| Dec 2023 | 13 |
| Jan 2024 | 13 |
| Feb 2024 | 13 |
| Mar 2024 | 13 |
| Apr 2024 | 13 |
| May 2024 | 13 |
| Jun 2024 | 13 |
| Jul 2024 | 13 |
InMed Pharmaceuticals other data
3.57%
-9.81%
of INM is owned by hedge funds
82.07K
-33.73K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 79100 | 0 |
| Jul 2024 | 0 | 240 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | MANCINI ALEXANDRA DIANE JANET other: Consultant | Common Stock | 240 | $0.18 | $42 | ||
Purchase | HULL ANDREW director | Common Stock | 37,500 | $0.39 | $14,625 | ||
Purchase | ADAMS ERIC A director, officer.. | Common Stock | 41,600 | $0.36 | $14,934 | ||
Purchase | ADAMS ERIC A director, officer.. | Common Stock | 41,600 | $0.36 | $14,934 | ||
Purchase | ADAMS ERIC A director, officer.. | Common Stock | 14,160 | $0.89 | $12,659 | ||
Purchase | ADAMS ERIC A director, officer.. | Common Stock | 14,160 | $0.89 | $12,659 | ||
Purchase | ADAMS ERIC A director, officer.. | Common Stock | 8,560 | $0.85 | $7,276 | ||
Purchase | ADAMS ERIC A director, officer.. | Common Stock | 8,560 | $0.85 | $7,276 | ||
Purchase | COLWILL BRUCE officer: CFO | Common Stock | 5,000 | $1.09 | $5,440 | ||
Purchase | JOHNSON SHANE AARON officer: SVP, GM of BayMedica LLC | Common Stock | 8,500 | $1.26 | $10,710 |
| Patent |
|---|
Application Filling date: 6 Mar 2020 Issue date: 2 Jun 2022 |
Application Filling date: 21 Sep 2018 Issue date: 17 Sep 2020 |
Application Filling date: 5 Sep 2018 Issue date: 17 Sep 2020 |
Application Filling date: 8 May 2018 Issue date: 28 May 2020 |
| Quarter | Transcript |
|---|---|
| Q4 2022 23 Sep 2022 | Q4 2022 Earnings Call Transcript |
| Q2 2022 15 Feb 2022 | Q2 2022 Earnings Call Transcript |
| Q4 2021 24 Sep 2021 | Q4 2021 Earnings Call Transcript |
| Q3 2021 16 May 2021 | Q3 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Eric A. Adams (1964) Pres, Chief Executive Officer & Director | $488,440 |
Mr. Bruce S. Colwill C.A., CPA, CA (1965) Chief Financial Officer & Corporation Sec. | $397,540 |
| Ms. Alexandra Diane-Janet Mancini (1953) Senior Vice President of Clinical & Regulatory Affairs | $337,130 |
-
What's the price of InMed Pharmaceuticals stock today?
One share of InMed Pharmaceuticals stock can currently be purchased for approximately $2.25.
-
When is InMed Pharmaceuticals's next earnings date?
Unfortunately, InMed Pharmaceuticals's (INM) next earnings date is currently unknown.
-
Does InMed Pharmaceuticals pay dividends?
No, InMed Pharmaceuticals does not pay dividends.
-
How much money does InMed Pharmaceuticals make?
InMed Pharmaceuticals has a market capitalization of 3.15M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 11.18% to 4.6M US dollars.
-
What is InMed Pharmaceuticals's stock symbol?
InMed Pharmaceuticals Inc. is traded on the NASDAQ under the ticker symbol "INM".
-
What is InMed Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of InMed Pharmaceuticals?
Shares of InMed Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are InMed Pharmaceuticals's key executives?
InMed Pharmaceuticals's management team includes the following people:
- Mr. Eric A. Adams Pres, Chief Executive Officer & Director(age: 61, pay: $488,440)
- Mr. Bruce S. Colwill C.A., CPA, CA Chief Financial Officer & Corporation Sec.(age: 60, pay: $397,540)
- Ms. Alexandra Diane-Janet Mancini Senior Vice President of Clinical & Regulatory Affairs(age: 72, pay: $337,130)
-
How many employees does InMed Pharmaceuticals have?
As Jul 2024, InMed Pharmaceuticals employs 13 workers.
-
When InMed Pharmaceuticals went public?
InMed Pharmaceuticals Inc. is publicly traded company for more then 11 years since IPO on 5 May 2014.
-
What is InMed Pharmaceuticals's official website?
The official website for InMed Pharmaceuticals is inmedpharma.com.
-
Where are InMed Pharmaceuticals's headquarters?
InMed Pharmaceuticals is headquartered at 815 West Hastings Street, Vancouver, BC.
-
How can i contact InMed Pharmaceuticals?
InMed Pharmaceuticals's mailing address is 815 West Hastings Street, Vancouver, BC and company can be reached via phone at +60 4 669 7207.
InMed Pharmaceuticals company profile:
InMed Pharmaceuticals Inc.
inmedpharma.comExchange:
NASDAQ
Full time employees:
13
Industry:
Biotechnology
Sector:
Healthcare
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
815 West Hastings Street
Vancouver, BC V6C 1B4
Vancouver, BC V6C 1B4
CIK: 0001728328
ISIN: CA4576376012
CUSIP: 457637601
